Ultragenyx Pharmaceutical Inc. buy Royal Bank of Canada
Start price
22.04.24
/
50%
€41.20
Target price
22.04.25
€72.35
Performance (%)
0.97%
Price
25.07.24
€41.60
Summary
This prediction is currently active. The BUY prediction by Royal_Bank_of_Canada for Ultragenyx Pharmaceutical Inc. is nearly unchanged. This prediction currently runs until 22.04.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Ultragenyx Pharmaceutical Inc. | 6.122% | 6.122% |
iShares Core DAX® | 1.280% | 1.320% |
iShares Nasdaq 100 | -2.457% | -5.192% |
iShares Nikkei 225® | -2.006% | -1.389% |
iShares S&P 500 | -0.662% | -1.884% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
Ratings data for RARE provided by MarketBeat